Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/o0, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

_	of entity		
Gold	fields Money Limited		
ABN			
63 08	87 651 849		
We (	the entity) give ASX the followin	g information.	
Part	1 - All issues		
	1 - All issues ust complete the relevant sections (attac	ch sheets if there is not enough space).	
You m	ust complete the relevant sections (attac		
	*Class of *securities issued or to	Performance Rights	
You m	ust complete the relevant sections (attac		
You m	*Class of *securities issued or to		
You m	ust complete the relevant sections (attack  +Class of +securities issued or to be issued  Number of +securities issued or		
You m	*Class of *securities issued or to be issued  Number of *securities issued or to be issued (if known) or	Performance Rights	
You m	ust complete the relevant sections (attack  +Class of +securities issued or to be issued  Number of +securities issued or	Performance Rights	
You m	*Class of *securities issued or to be issued  Number of *securities issued or to be issued (if known) or maximum number which may	Performance Rights	

<sup>+</sup> See chapter 19 for defined terms.

Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, amount outstanding and due if dates for payment; +convertible securities, the conversion price and dates for conversion)

Performance Rights are granted to senior executives pursuant to the Goldfields Money Equity Incentive Plan approved on 18 November 2016 at the Annual General Meeting.

The Participant may exercise vested Performance Rights for the period up until 29 November 2021. Any unexercised Performance Rights will lapse on 30 November 2021.

Upon exercise, the Company will deliver the Participant fully paid ordinary Shares which will be either purchased on-market or issued from the capital of the Company at the election of the Board.

Generally, Performance Rights that have not vested will lapse on the earlier of:

- a relevant Performance Condition not being met by 29 November 2021; or
- if the Participant ceases employment with the Company.

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Performance Rights are not quoted securities and do not rank equally with ordinary shares or any other class of quoted securities. Performance Rights do not confer a right to vote, a right to receive dividends or any other rights of a shareholder. Any ordinary share issued or transferred to the holder of a Performance Right upon vesting will rank equally from the date of allotment with other ordinary shares.

5 Issue price or consideration

The Eligible Employees were not required to pay for the grant of the Performance Rights and for each Performance Right that vests, the Eligible Employee will be entitled to receive one share in the Company without payment.

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

Performance Rights are granted as long term equity incentives to senior executives in accordance with the Goldfields Money Long Term Incentive Plan.

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

res

If Yes, complete sections 6b – 6h in relation to the \*securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

At the 18 November 2016 Annual General Meeting

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

6c	Number of *securities issued without security holder approval under rule 7.1	Nil	
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	1,700,000	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See attached.	
	±1 1.	D.C. D.L.	. 1
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	Performance Rights v February 2017	vere granted on 9
		Number	+Class

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)  Performance Rights  1,700,000  Performance Rights  1,700,000  Performance Rights issued in this announcement  Not applicable  Part 2 - Pro rata issue  Is security holder approval required?  Not applicable  Not applicable	8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	18,016,853	Fully paid ordinary shares
9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)  4,500,000  Performance Rights 1,700,000  Performance Rights issued in this announcement  10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)  Part 2 - Pro rata issue  11 Is security holder approval required?  12 Is the issue renounceable or non-renounceable?  13 Ratio in which the *securities will be offered  14 *Class of *securities to which the offer relates  15 *Record date to determine entitlements  Not applicable				
*securities not quoted on ASX (including the *securities in section 2 if applicable)  10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)  10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)  11 Is security holder approval required?  12 Is the issue renounceable or non-renounceable?  13 Ratio in which the *securities will be offered  14 *Class of *securities to which the offer relates  15 *Record date to determine entitlements  16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  17 Policy for deciding entitlements  Not applicable  Not applicable  Not applicable  Not applicable			Number	+Class
(including the *securities in section 2 if applicable)  10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)  Part 2 - Pro rata issue  11 Is security holder approval required?  12 Is the issue renounceable or non-renounceable?  13 Ratio in which the *securities will be offered  14 *Class of *securities to which the offer relates  15 *Record date to determine entitlements  16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  17 Policy for deciding entitlements  Not applicable  Not applicable  Not applicable  Not applicable	9		4,500,000	Options expiring 11
section 2 if applicable)  40,000  FY2017 Annual Performance Rights 1,700,000  Performance Rights issued in this issued in this announcement  Not applicable  Part 2 - Pro rata issue  Is security holder approval required?  Is the issue renounceable or non-renounceable?  Ratio in which the *securities will be offered  *Class of *securities to which the offer relates  **Record date to determine entitlements  Not applicable  Not applicable  Not applicable  Not applicable  Not applicable				May 2019
issued in this announcement  Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)  Part 2 - Pro rata issue  Is security holder approval required?  Not applicable  Is the issue renounceable or non-renounceable?  Ratio in which the *securities will be offered  *Class of *securities to which the offer relates  *Class of *securities to which the offer relates  *Record date to determine entitlements  Not applicable  Not applicable  Not applicable  Not applicable			40,000	-
Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)  Part 2 - Pro rata issue  Is security holder approval required?  Is the issue renounceable or nonrenounceable?  Ratio in which the *securities will be offered  *Class of *securities to which the offer relates  *Record date to determine entitlements  Not applicable  Not applicable  Not applicable  Not applicable  Not applicable			1,700,000	issued in this
trust, distribution policy) on the increased capital (interests)  Part 2 - Pro rata issue  Is security holder approval required?  Is the issue renounceable or non-renounceable?  Is the issue renounceable or non-renounceable?  Not applicable  Not applicable  Value offered  Not applicable  Not applicable  Not applicable  Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  Not applicable  Not applicable				announcement
Is security holder approval required?  Is the issue renounceable or non-renounceable?  Not applicable  Policy for deciding entitlements  Not applicable	10	trust, distribution policy) on the	Not applicable	
renounceable?  Ratio in which the *securities will be offered  **Class of *securities to which the offer relates  **Record date to determine entitlements  **Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?  Not applicable  Not applicable  Not applicable		Is security holder approval	Not applicable	
will be offered  +Class of *securities to which the offer relates  Not applicable  *Record date to determine entitlements  Not applicable  Not applicable  Not applicable  Not applicable  Policy for deciding entitlements  Not applicable  Not applicable	12		Not applicable	
offer relates  †Record date to determine entitlements  Not applicable  Not applicable  Not applicable  Not applicable  Policy for deciding entitlements  Not applicable	13		Not applicable	
entitlements  Not applicable  Not applicable  registers (or subregisters) be aggregated for calculating entitlements?  Policy for deciding entitlements  Not applicable	14		Not applicable	
registers (or subregisters) be aggregated for calculating entitlements?  Policy for deciding entitlements Not applicable	15		Not applicable	
	16	registers (or subregisters) be aggregated for calculating	Not applicable	
	17		Not applicable	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	Not applicable
19	Closing date for receipt of acceptances or renunciations	Not applicable
20	Names of any underwriters	Not applicable
21	Amount of any underwriting fee or commission	Not applicable
22	Names of any brokers to the issue	Not applicable
23	Fee or commission payable to the broker to the issue	Not applicable
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable
28	Date rights trading will begin (if applicable)	Not applicable
29	Date rights trading will end (if applicable)	Not applicable

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	Not applicable	
33	<sup>+</sup> Issue date	Not applicable	
Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities			
34	Type of *securities (tick one)		
(a)	+Securities described in Part	: 1	
(b)	All other *securities  Example: restricted securities at the e	nd of the escrowed period, partly paid securities that become fully paid,	
		en restriction ends, securities issued on expiry or conversion of convertible	
Entities that have ticked box 34(a)			
Additional securities forming a new class of securities			
Tick to docume	indicate you are providing the informatents	tion or	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories	
	1,001 - 5,000 5,001 - 10,000		
	10,001 - 100,000		

<sup>+</sup> See chapter 19 for defined terms.

	100,001 and over		
37	A copy of any trust deed for t	he additional <sup>+</sup> securities	
Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought	Not applicable	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	Not applicable	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Not applicable	
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another *security, clearly identify	Not applicable	
	that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number Not applicable	+Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 10 February 2017

(Company secretary)

Print name: ...Michael Verkuylen......

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B - Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	18,016,853	
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2	Nil	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period	Nil	
"A"	18,016,853	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	2,702,527	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	Nil	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	2,702,527	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	2,702,527	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

from which the placement  3,016,853  10  tote: this value cannot be changed		
10		
ote: this value cannot be changed		
801,685		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
il		

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	1,801,685	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	1,801,685	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.